Dipharma Inc. Merges Kalexsyn, Inc. into Parent to Complete Integration

Chemstream Acquires Synthex Organics

October 26, 2025

Manufacturing

Chemstream has merged with and acquired Synthex Organics, combining Chemstream's chemical distribution, logistics and fluid systems capabilities with Synthex's specialty chemical manufacturing and R&D. The combined company will operate under the Chemstream name with integrated operations and expanded R&D and manufacturing hubs across multiple U.S. states to better serve oil & gas, water treatment, pulp & paper and mining customers.

Infosys Acquires Kaleidoscope Innovation

September 3, 2020

Engineering Services

Infosys has signed a definitive agreement to acquire Kaleidoscope Innovation, a Cincinnati-based product design and development firm that serves medical, consumer and industrial markets. The acquisition expands Infosys' engineering services portfolio by adding upstream product innovation, human factors and medical device design capabilities to its global product engineering offerings.

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

December 11, 2024

Biotechnology

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.

Symeres Acquires DGr Pharma

September 15, 2025

Healthcare Services

Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.

ARCHIMED Acquires and Merges Symbio and Proinnovera to Form Symbio Proinnovera

November 17, 2023

Healthcare Services

ARCHIMED has acquired US-based Symbio and Germany-based Proinnovera in an all-equity deal and merged them to create Symbio Proinnovera, a specialized dermatology-focused CRO. The combined group will offer end-to-end dermatology consulting, formulation, testing and clinical research across North America and Europe, with founders rolling equity into the new platform and ARCHIMED-appointed operating partners joining the board to drive growth and further acquisitions.

Symeres Acquires Organix Inc.

April 26, 2022

Biotechnology

Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.